title: MUC5AC mucin release from human airways in vitro: effects of indomethacin and Bay X1005.
abstract: BACKGROUND
  Increased secretion of mucus is a hallmark of many respiratory diseases and contributes significantly to the airflow limitation experienced by many patients. While the current pharmacological approach to reducing mucus and sputum production in patients is limited, clinical studies have suggested that drugs which inhibit the cyclooxygenase and/or 5-lipoxygenase enzymatic pathways may reduce secretory activity in patients with airway disease.
  
  
  OBJECTIVE
  This study was performed to investigate the effects of indomethacin (cyclooxygenase inhibitor) and Bay x 1005 (5-lipoxygenase inhibitor) on MUC5AC release from human airways in vitro.
  
  
  METHODS
  An immunoradiometric assay was used to determine the quantities of MUC5AC present in the biological fluids derived from human airways in vitro. The measurements were made with a mixture of eight monoclonal antibodies (MAbs; PM8) of which the 21 M1 MAb recognized a recombinant M1 mucin partially encoded by the MUC5AC gene.
  
  
  RESULTS
  The quantities of MUC5AC detected in the biological fluids derived from human bronchial preparations were not modified after treatment with indomethacin (cyclooxygenase inhibitor) and/or an inhibitor of the 5-lipoxygenase metabolic pathway (BAY x 1005).
  
  
  CONCLUSIONS
  These results suggest that the cyclooxygenase and 5-lipoxygenase metabolic pathways play little or no role in the release of MUC5AC from human airways.
authors.affiliation: Laboratoire de Pharmacologie Pulmonaire, CNRS-ESA 8078, H pital Marie Lannelongue, Le Plessis Robinson, France.
authors.forename: P
authors.initials: P
authors.lastname: Roger
authors.forename: J P
authors.initials: JP
authors.lastname: Gascard
authors.forename: J
authors.initials: J
authors.lastname: Bara
authors.forename: V T
authors.initials: VT
authors.lastname: de Montpreville
authors.forename: C
authors.initials: C
authors.lastname: Brink
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D001980:Bronchi / Q000378:metabolism*; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D007213:Indomethacin / Q000494:pharmacology*; D016859:Lipoxygenase Inhibitors; D055271:Mucin 5AC; D009077:Mucins / Q000378:metabolism*; D011804:Quinolines / Q000494:pharmacology*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D016859:Lipoxygenase Inhibitors; C524678:MUC5AC protein, human; D055271:Mucin 5AC; D009077:Mucins; D011804:Quinolines; C079315:2-(4-(quinolin-2-yl-methoxy)phenyl)-2-cyclopentylacetic acid; D007213:Indomethacin